Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAR-200 plus cetrelimab versus cetrelimab alone before radical cystectomy in muscle-invasive bladder cancer
NL-OMON60856Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2022
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in transitional cell carcinoma of the bladder (TCC) and muscle-invasive bladder cancer (MIBC) comparing Cohort 1: TAR-200 + cetrelimab with Cohort 2: cetrelimab alone (2 cohorts). Primary endpoint: Pathologic complete response rate at radical cystectomy. Started Jan 2022; status: completed.
02
Drugs
cetrelimabgemcitabine-releasing intravesical systemgemcitabine
03
Conditions
transitional cell carcinoma of the bladder (TCC)muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on NL-OMON60856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60856.